Chemotherapy for children with medulloblastoma

Area of Science:

• Pediatric Oncology
• Neuro-oncology
• Clinical Trial Methodology

Background:

• Standard care for pediatric medulloblastoma involves post-surgical radiotherapy (RT) and chemotherapy.
• Chemotherapy aims to enhance survival and mitigate RT-related adverse effects.
• Treatment modifications include reduced RT doses/fields or omission in specific pediatric age groups.

Purpose of the Study:

• To compare event-free survival/disease-free survival (EFS/DFS) and overall survival (OS) in children with medulloblastoma receiving chemotherapy versus those not receiving it.
• To compare EFS/DFS and OS between standard-dose RT without chemotherapy and reduced-dose RT with chemotherapy.
• To assess adverse effects of chemotherapy and RT, including long-term impacts and quality of life.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) in children (0-21 years) with medulloblastoma.
• Searched CENTRAL, MEDLINE/PubMed, and EMBASE databases up to August 2013.
• Independent data extraction and risk of bias assessment by two reviewers.

Main Results:

• Seven RCTs (1080 children) evaluated chemotherapy with RT versus RT alone. Meta-analyses showed no consistent significant difference in EFS/DFS or OS, depending on event definition.
• One RCT comparing standard-dose RT vs. reduced-dose RT with chemotherapy found no significant EFS/DFS difference.
• Chemotherapy groups showed increased risk of severe infections and fever/neutropenia; other adverse effects and quality of life were not definitively different or evaluated.

Conclusions:

• A benefit of chemotherapy in pediatric medulloblastoma cannot be excluded, but definitive conclusions are limited by study heterogeneity, evolving treatments, and potential biases.
• The review highlights 'no evidence of effect' does not equate to 'evidence of no effect', citing potential issues like low statistical power or insufficient follow-up.
• More high-quality research is necessary to establish optimal treatment strategies, considering specific agents, radiation doses, and patient subgroups.